LncRNA HEIH Enhances Paclitaxel-Tolerance of Endometrial Cancer Cells via Activation of MAPK Signaling Pathway
This study aimed to investigate the function of lncRNA HEIH on promoting endometrial cancer cells’ tolerance of paclitaxel (PTX). LncRNA HEIH expression was measured by QRT-PCR in endometrial cancer tissues, human healthy tissues and cell lines. The PTX-resistant endometrial cancer cells (Ishikawa-RE and HHUA-RE) were intermittently exposed to increase concentrations of PTX and were constructed as evidenced by MTT assay. Besides, the specific siRNA of HEIH (siHEIH) and pcDNA3.1-HEIH plasmid transfection were utilized to alter the expression of HEIH in the cells and investigate the effects of HEIH on resistance to PTX in endometrial cancer cells. Moreover, MTT, colony formation and apoptosis analysis were taken advantage to evaluate cell viability and proliferation when treated with PTX. Then, differential genes in PTX-resistant and HEIH-knock-down PTX-resistant endometrial cancer cells were screened out by microarray analysis. Finally, gene-set enrichment analysis was used to predict the promising signaling pathway of HEIH and western blotting analysis were performed to verify the relevant genes expression of MAPK signaling pathway. LncRNA HEIH, the dysregulation of which involved in production of drug-resistance, was overexpressed in PTX-resistant endometrial cancer cells. Up-regulating HEIH would activate MAPK pathway, promote chemo-resistance of endometrial cancer cells and enhance cell proliferation and viability, whereas silencing HEIH depressed the MAPK signaling pathway, contributed to restoring chemo-sensitivity to PTX and repressed cell physiological process. Down-regulating lncRNA HEIH expression reversed the PTX-resistance of endometrial cancer cells through MAPK signaling pathway.
KeywordsEndometrial cancer HEIH Paclitaxel resistance MAPK signaling pathway
JG, TT and JL: conception and design, analysis and interpretation of data; YY and LZ: drafting the article; YQ: revising it critically for important intellectual content. YQ is the guarantor.
This study was funded by New Bud Science Foundation(KX104), West China Second University Hospital, Sichuan University.
Compliance with Ethical Standards
All procedures performed in studies involving human participants were in accordance with the ethical standards of the committee of West China Second University Hospital and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
Informed consent was obtained from all individual participants included in the study.
Conflict of Interest
The authors declare that they have no conflict of interest.
- 2.Kharma B, Baba T, Mandai M, Matsumura N, Murphy SK, Kang HS, Yamanoi K, Hamanishi J, Yamaguchi K, Yoshioka Y, Konishi I (2013) Utilization of genomic signatures to identify high-efficacy candidate drugs for chemorefractory endometrial cancers. Int J Cancer 133(9):2234–2244. https://doi.org/10.1002/ijc.28220 CrossRefPubMedGoogle Scholar
- 3.Viswanathan AN, Moughan J, Miller BE, Xiao Y, Jhingran A, Portelance L, Bosch WR, Matulonis UA, Horowitz NS, Mannel RS, Souhami L, Erickson BA, Winter KA, Small W Jr, Gaffney DK (2015) NRG oncology/RTOG 0921: a phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer. Cancer 121(13):2156–2163. https://doi.org/10.1002/cncr.29337 CrossRefPubMedPubMedCentralGoogle Scholar
- 5.Reyes HD, Miecznikowski J, Gonzalez-Bosquet J, Devor EJ, Zhang Y, Thiel KW, Samuelson MI, McDonald M, Stephan JM, Hanjani P, Guntupalli S, Tewari KS, Backes F, Ramirez N, Fleming GF, Filiaci V, Birrer MJ, Leslie KK (2017) High stathmin expression is a marker for poor clinical outcome in endometrial cancer: an NRG oncology group/gynecologic oncology group study. Gynecol Oncol 146(2):247–253. https://doi.org/10.1016/j.ygyno.2017.05.017 CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Zhao H, Xing G, Wang Y, Luo Z, Liu G, Meng H (2017) Long noncoding RNA HEIH promotes melanoma cell proliferation, migration and invasion via inhibition of miR-200b/a/429. Biosci Rep 37(3). https://doi.org/10.1042/BSR20170682
- 16.Yang F, Zhang L, Huo XS, Yuan JH, Xu D, Yuan SX, Zhu N, Zhou WP, Yang GS, Wang YZ, Shang JL, Gao CF, Zhang FR, Wang F, Sun SH (2011) Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. Hepatology 54(5):1679–1689. https://doi.org/10.1002/hep.24563 CrossRefPubMedGoogle Scholar
- 18.Haque SU, Niu L, Kuhnell D, Hendershot J, Biesiada J, Niu W, Hagan MC, Kelsey KT, Casper KA, Wise-Draper TM, Medvedovic M, Langevin SM (2018) Differential expression and prognostic value of long non-coding RNA in HPV-negative head and neck squamous cell carcinoma. Head Neck 40(7):1555–1564. https://doi.org/10.1002/hed.25136 CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Tanaka T, Toujima S, Tanaka J (2012) Differential sensitivity to paclitaxel-induced apoptosis and growth suppression in paclitaxel-resistant cell lines established from HEC-1 human endometrial adenocarcinoma cells. Int J Oncol 41(5):1837–1844. https://doi.org/10.3892/ijo.2012.1600 CrossRefPubMedGoogle Scholar
- 23.Liu Z, Sun M, Lu K, Liu J, Zhang M, Wu W, De W, Wang Z, Wang R (2013) The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregualtion of p21(WAF1/CIP1) expression. PLoS One 8(10):e77293. https://doi.org/10.1371/journal.pone.0077293 CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Noel JK, Crean S, Claflin JE, Ranganathan G, Linz H, Lahn M (2008) Systematic review to establish the safety profiles for direct and indirect inhibitors of p38 mitogen-activated protein kinases for treatment of cancer. A systematic review of the literature. Med Oncol 25(3):323–330. https://doi.org/10.1007/s12032-008-9039-1 CrossRefPubMedGoogle Scholar
- 27.Bai L, Mao R, Wang J, Ding L, Jiang S, Gao C, Kang H, Chen X, Sun X, Xu J (2015) ERK1/2 promoted proliferation and inhibited apoptosis of human cervical cancer cells and regulated the expression of c-Fos and c-Jun proteins. Med Oncol 32(3):57. https://doi.org/10.1007/s12032-015-0490-5 CrossRefPubMedGoogle Scholar
- 28.Liu C, Ding L, Bai L, Chen X, Kang H, Hou L, Wang J (2017) Folate receptor alpha is associated with cervical carcinogenesis and regulates cervical cancer cells growth by activating ERK1/2/c-Fos/c-Jun. Biochem Biophys Res Commun 491(4):1083–1091. https://doi.org/10.1016/j.bbrc.2017.08.015 CrossRefPubMedGoogle Scholar